Jupiter Neurosciences Faces Delisting Concerns

Ticker: JUNS · Form: 8-K · Filed: 2025-03-25T00:00:00.000Z

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

TL;DR

Jupiter Neurosciences might get delisted, big trouble for the stock.

AI Summary

Jupiter Neurosciences, Inc. filed an 8-K on March 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as Jupiter Orphan Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in Jupiter, Florida.

Why It Matters

This filing indicates potential issues with Jupiter Neurosciences' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.

Key Numbers

Key Players & Entities

FAQ

What specific listing rule or standard has Jupiter Neurosciences failed to satisfy?

The filing does not specify the exact rule or standard that Jupiter Neurosciences has failed to satisfy, only that a notice has been issued.

What is the expected timeline for addressing the delisting concerns?

The filing does not provide a specific timeline for addressing the delisting concerns.

Has Jupiter Neurosciences taken any steps to rectify the situation leading to the notice?

The filing does not detail any specific actions taken by Jupiter Neurosciences to rectify the situation.

What are the potential consequences if the company cannot satisfy the listing requirements?

The primary consequence would be the delisting of the company's securities from the exchange where they are currently listed.

When was the company formerly known as Jupiter Orphan Therapeutics, Inc.?

The company's name changed from Jupiter Orphan Therapeutics, Inc. on July 13, 2016.

From the Filing

0001641172-25-000627.txt : 20250325 0001641172-25-000627.hdr.sgml : 20250325 20250325171625 ACCESSION NUMBER: 0001641172-25-000627 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250321 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250325 DATE AS OF CHANGE: 20250325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 25769309 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm false 0001679628 0001679628 2025-03-21 2025-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   March 21, 2025 Date of Report (Date of earliest event reported)   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   001-41265   47-4828381 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   1001 North US HWY 1 , Suite 504 , Jupiter , FL   33477 (Address of principal executive offices)   (Zip Code)   (561) 406-6154 Registrant’s telephone number, including area code   Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging Growth Company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing   On March 21, 2025, Jupiter Neurosciences, Inc. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ.   Listing Rule 5

View on Read The Filing